70 results about "Mouse Intestine" patented technology

The invention discloses application of Akkermansia Muciniphila in preparing a drug or health-care product for preventing and treating depression. In the application, in vivo pharmacodynamic research is performed on the effect of the Akkermansia Muciniphila in incidence of the depression and depression resistance; a result shows that abundance of the Akkermansia Muciniphila in an intestinal tract of a patient with the depression is obviously lowered; and a result of an animal experiment shows that abundance of the Akkermansia Muciniphila in an intestinal tract of a mouse with the depression isremarkably lowered. In the application disclosed by the invention, the Akkermansia Muciniphila is transplanted into a model of the mouse with the depression; and tests show that through Akkermansia Muciniphila transplantation, a movement distance of the mouse can be increased, the immobility times of a tail suspension test and a forced swimming test can be shortened, the depression state of the mouse is remarkably relieved, and the Akkermansia Muciniphila shows very good anti-depression curative effect without side effect.

The invention discloses lactobacillus plantarum with a function of removing patulin and belongs to the technical field of microorganisms. The lactobacillus plantarum disclosed by the invention has acid resistance and can be used for removing patulin from an aqueous solution. When 1*10<10>CFU / mL of lactobacillus plantarum is cultured together with 1000mu g / L patulin for 4 hours, the lactobacillus plantarum can remove more than 80% of the patulin, and when 1*10<10>CFU / mL of lactobacillus plantarum is cultured together with 1000mug / L patulin for 8 hours, the lactobacillus plantarum can remove more than 90% of the patulin. In addition, the lactobacillus plantarum has the functions of significantly reducing the patulin in apple juice and moldy apple pomace and alleviating the influence of the patulin on intestinal microflora of mice. The lactobacillus plantarum is used for removing patulin in foods or feeds and has very broad application prospect.

The invention discloses lactobacillus rhamnosus and an application thereof. The lactobacillus rhamnosus is named as lactobacillus rhamnosus AU9260 in taxonomy, and the preservation number of the lactobacillus rhamnosus is CGMCC No.21662. The strain has excellent in-vitro probiotic characteristics such as simulated gastrointestinal fluid tolerance, bacteriostatic activity, adhesion to Caco-2 cells and the like, and is preliminarily judged to be safe. In addition, the strain has a potential function of relieving and / or preventing allergic diseases of hosts, can significantly reduce histamine, specific IgE and cell factors in serum of mice induced and sensitized by beta-lactoglobulin, and can also protect damage to intestinal mucosa structures of the mice caused by allergy and regulate intestinal flora structures. The lactobacillus rhamnosus can be used as foods and / or health-care foods with a desensitization effect.

The invention relates to bifidobacterium longum subspecies CCFM687, fermented food and application thereof. Bifidobacterium longum infantile subspecies CCFM687 of the present invention can improve the depression-like behavior of depressed mice, improve the levels of 5-hydroxytryptamine, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice; improve depression Butyric acid content in the gut of mice; lower intestinal abundance of Desulfovibrio spp., increased abundance of Bifidobacterium and S24‑7 families, increased gut microbiota α‑diversity, and improved intestinal Intestinal flora disorder, reduce the occurrence of autism, inflammatory bowel disease, obesity and type I diabetes; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the 5-hydroxychromatin level of the cells The secretion of amino acid provides precursor substances for the synthesis of 5-hydroxytryptamine in the brain. Therefore, it has broad application value.

The invention provides a preparation method of a mice intestinal flora alteration ERIC-PCR (Enterobacterial Repetitive Intergenic Consensus sequence-based Polymerase Chain Reaction) fingerprint spectrum. The preparation method comprises the steps: moulding mice intestinal flora alteration caused by antibacterial-associated diarrhea, extracting a cecum content DNA, eliminating humic acid in the cecum content DNA, eliminating a PCR inhibitor in the cecum content DNA, performing ERIC-PCR amplification and native polyacrylamide gel electrophoresis (Native-PAGE), and comparing with a conventional flora analysis result so as to establish the ERIC-PCR fingerprint spectrum of the mice intestinal flora alteration. According to the preparation method, with a pure-series mice as a research object, the defect caused when a conventional bacterium culturing method is applied to the microflora analysis is solved. The preparation method can be used for rapid detection of the laboratory mice intestinal flora alteration, prevents the defects of complicated operation, long time consumption, large workload and the like of conventional bacterium separation and culturing, and is capable of accurately, rapidly and effectively detecting the mice intestinal flora distribution condition.

The invention relates to the fields of medical treatment evaluation and detection technology, and in particular relates to a method for preparing an intestinal mucosa injury animal model and applications of the prepared intestinal mucosa injury animal model. According to the scheme, the medicine L-MSO having good water solubility and realizing convenient and simple gavaging operation is adopted, the mouse intestinal mucosa injury is conveniently and stably induced, and meanwhile, the corresponding tissue pathological change and inflammatory factor change are caused. For the preparation method provided by the invention, the intestinal mucosa injury animal model is prepared from the metabolism injury direction obviously different from the molding direction of immune injury inducing in the prior art, particularly, the low-concentration L-MSO is adopted for preparing the common injured model, wherein the intestinal mucosa of the laboratory mouse has the mild-moderate injury, the high-concentration L-MSO is adopted for preparing the seriously injured model, wherein the intestinal mucosa of the laboratory mouse has the severe injury; the prepared intestinal mucosa injury model has the significant values for the research and practice of inflammatory bowel diseases.

The invention discloses lactobacillus paracasei capable of relieving alcoholic intestinal injury and an application of the lactobacillus paracasei capable of relieving alcoholic intestinal injury, andbelongs to the technical field of microorganisms and medicines, The invention provides a medicine capable of preventing and / or treating alcoholic intestinal injury or alcoholic liver injury. Effective components of the medicine are lactobacillus paracasei CCFM1120, and the lactobacillus paracasei CCFM1120 can effectively relieve the alcoholic intestinal injury and the alcoholic liver injury. Thelactobacillus paracasei has the specific effects that the mRNA expression level of intestine tight junction proteins of alcohol modeled mice can be notably increased, the content of endotoxin in serumof the alcohol modeled mice can be notably reduced, the activity of alanine aminotransferase and aspartate aminotransferase in the serum of the alcohol modeled mice can be notably reduced, the oxidation stress level of the liver of the alcohol modeled mice can be notably reduced, and the pathology damage of liver tissue of the alcohol modeled mice can be notably improved.

The invention discloses multifunctional pediococcus pentosaceus CCFM1107 for relieving toxic actions of PFOS (perfluorooctane sulfonate) and a fermentation food and application of CCFM1107. The pediococcus pentosaceus CCFM1107 disclosed by the invention has a very good adsorption capability upon PFOS in vitro to reduce the concentration of PFOS, has a good capability in eliminating diphenyl trinitrophenyl hydrazyl free radicals and hydroxyl free radicals, and a reduction capability, and is capable of relieving hepatomegaly caused by exposure of PFOS to mice, reducing the content of a TNF-alpha(tumor necrosis factor-alpha) in the liver, relieving intestinal flora disturbance, reducing the abundance of S24-7 families, lactobacillus, bifidobacterium and parabacteroides in intestines of the mice, and reducing the occurrence tendency of diseases such as liver diseases, hypertension, diabetes and obesity.

The invention relates to a low-cost mouse intestinal organ culture medium and a culture method, and belongs to the technical field of cell biology. The culture medium for the mouse intestinal organs mainly comprises a basal culture medium, a 293T-HA-Rspo1-Fc cell supernatant and an additive. The culture method of the mouse intestinal organs comprises the following steps: pretreating mouse intestines to prepare cell clusters; resuspending the cell clusters by using the mixed solution of the mouse intestinal organ culture medium and matrix gel; and inoculating the cell clusters into a culture medium for culturing. The cytokines added into the culture medium are all mouse sources and are closer to the normal growth state in vivo, so that growth of organoid in a morphological structure can bemaintained. Besides, the 293T-HA-Rspo1-Fc cell supernatant is used for replacing an expensive cell factor RSpondin 1, so that the cost is low, and large-scale production is facilitated.

The invention discloses multifunctional pediococcus acidilactici CCFM1105, fermented food produced from the multifunctional pediococcus acidilactici CCFM1105 and application of the multifunctional pediococcus acidilactici CCFM1105. The pediococcus acidilactici CCFM1105 has excellent capability of adsorbing PFOS in vitro so that the concentration of the PFOS can be decreased, has good capability ofscavenging 1,1-diphenyl-2-picrylhydrazyl free radicals and scavenging hydroxyl free radicals and good reducing capability, improves hepatomegaly, caused by exposure to PFOS, of mice, raises the levels of CAT, SOD and antioxidant capability, improves intestinal flora disturbance, reduces abundance of an S24-7 family, lactobacillus, bifidobacterium and parabacteroides in intestinal tracts of mice,and reduces the incidences of diseases of liver diseases, hypertension, diabetes, obesity and the like.

The invention belongs to the technical field of medicines, and particularly relates to application of pectolinarin in preparation of a medicine for treating glycolipid metabolism diseases and a medicinal composition. According to the application of the pectolinarin in preparation of the medicine for treating the glycolipid metabolism diseases, experiments prove that the pectolinarin has the effects of reducing blood sugar of mice suffering from glycolipid metabolism disorder, regulating blood fat, reducing weight and reducing abdominal girth, can also promote L cells of intestinal tracts of the mice to secrete hypoglycemic hormone GLP-1 to achieve the effect of enhancing the insulin sensitivity, and can effectively treat the glycolipid metabolism diseases. The invention also provides the medicinal composition containing the pectolinarin. The medicinal composition comprises the pectolinarin and atractylenolide I. Compared with the pectolinarin, the medicinal composition has the advantages that the blood sugar is reduced, the blood fat is regulated, the effect of promoting the intestinal L cells to secrete the hypoglycemic hormone GLP-1 is more remarkable, and the medicinal composition has a good application prospect in the aspect of treating the glycolipid metabolism diseases.

The invention creatively provides an application of typhagoside in preparation of a medicine for treating inflammatory bowel diseases. According to the application disclosed by the invention, a DSS-induced C57BL / 6J mouse colitis model is treated by the typhagoside. Inflammation-related parameters such as weight loss, disease activity index and spleen weight of a mouse are improved, histological staining reveals that intestinal inflammation of the mouse is inhibited, and the pathological score is reduced. By further investigating a specific mechanism of anti-inflammatory effect, the result shows that the typhagoside can inhibit activation of an NF-kB pathway in mouse intestinal epithelial cells and reduce expression of inflammatory factors in the mouse intestinal epithelial cells. In conclusion, the Chinese herbal monomer typhagoside can provide a new way for preparing medicines for treating IBD and related diseases thereof in the future.

The invention discloses application of folium perillae extracts in preparation of a medicine for treating and / or preventing the inflammatory bowel disease. The folium perillae extracts disclosed by the invention have a reverse effect on diarrhea, hematochezia, weight loss and the colon position pathological injuries of a mouse with inflammatory bowel disease induced by low molecular weight dextransulfate, can obviously inhibit secretion of model mouse colon tissue cell factors NO, IFN-gamma, IL-4, IL-10 and IL-17, and can obviously inhibit the intestinal tissue MPO level of the model mouse.

The invention discloses a strain of bifidobacterium pseudocatenulatum capable of highly utilizing galactooligosaccharide and application of the bifidobacterium pseudocatenulatum, and belongs to the technical field of microorganisms and the technical field of medicines. The bifidobacterium pseudocatenulatum CCFM1170 obtained by screening in the invention can make high use of the galactooligosaccharide, which is specifically embodied in that: after the intervention of the galactooligosaccharide, the relative abundance of the strain in the intestinal tract of a source host is obviously improved; the strain shows stronger applicability, faster growth rate and shorter generation time in an in-vitro YCFA culture medium taking galactooligosaccharide as a carbon source, namely an intestinal microorganism in-vitro simulation culture method; according to the bifidobacterium pseudocatenulatum CCFM1170 disclosed by the invention, the galactooligosaccharide is highly utilized, so that the competitive adaptability of the bifidobacterium pseudocatenulatum CCFM1170 during intestinal colonization is improved; and the colonization strength and durability in the intestinal tract of a mouse are remarkably improved. Therefore, the bifidobacterium pseudocatenulatum CCFM1170 has a huge application prospect in the preparation of a product which has high colonization capability and is used for improving the health of the host.

The invention discloses multifunctional enterococcus faecium CCFM1106 and a feed additive thereof, and applications of the multifunctional enterococcus faecium CCFM1106 and the feed additive. The enterococcus faecium CCFM1106 has good adsorption capacity to PFOS in vitro to reduce the concentration of PFOS, has good diphenyl trinitrophenylhydrazine free radical and hydroxyl radical removal capacity and reducing capability, improves liver swelling of mice caused by PFOS exposure, improves levels of CAT, SOD and antioxidant capacity, improves intestinal flora disorder, reduces abundance of S24-7family, lactobacillus, bifidobacterium and bacteroides in intestinal tracts of the mice, and reduces occurrence tendency of diseases like liver diseases, hypertension, diabetes and obesity. The enterococcus faecium CCFM1106 can be used for preparing feed additives and medicines capable of relieving PFOS toxicity, and has extensive application prospect.

The invention relates to new application of mulberroside A and its derivative resveratrol in preparation of a drug for protecting the intestinal barrier. In the drug, the mulberroside A or the derivative thereof is an active ingredient. The influence of mulberroside A and its derivative on hippocampus neuroinflammation of high-fructose diet mice, the influence on intestinal barrier damage of high-fructose diet mice and the influence on intestinal flora disorder of high-fructose diet mice are studied through pharmacological experiments. It is found that the mulberroside A and its derivative canobviously inhibit activation of central microglial cells and inflammatory factor level of mice with high fructose diet. It is proved that the mulberroside A and its derivative have the effect of protecting the intestinal barrier, can be used for preparing a drug for preventing and / or treating central nervous inflammation and related neurodegenerative diseases caused by intestinal barrier damage,can remodel intestinal flora disorder caused by high fructose diet and are used for preparing a drug for adjusting intestinal flora disorder.

The invention discloses a mouse intestinal roll specimen preparation device and method, and relates to the technical field of animal specimen preparation. The mouse intestinal roll specimen preparation device comprises a winder and a wax strip, wherein the winder comprises a handle and a clamping base fixedly connected to one end of the handle, and an inserting hole is formed in the end, which isaway from the handle, of the clamping base; and one end of the wax strip is inserted into the inserting hole of the clamping base, and the other end of the wax strip extends out of the inserting holeof the clamping base. The mouse intestinal roll specimen preparation method is applied to the mouse intestinal roll specimen preparation device. The advantages are that 1, the Bouins liquid is used for carrying out pre-hardening treatment on the intestinal skin, so that the smoothness of the intestinal skin is favorably maintained, the pulling and pressing of the intestinal skin caused by the intestinal skin winding operation can be reduced, the operation difficulty during intestinal skin winding is reduced on the one hand, and the integrity of the intestinal morphological structure is guaranteed on the other hand; and 2, the preparation method of the intestinal roll is simple and easy to operate, consumes short time, can block endogenous or exogenous enzyme reaction in time, and is beneficial to ensuring the stability of protein in small intestine tissues;.

The invention provides a probiotic composition beneficial to improvement of immunity. The composition comprises lactobacillus rhamnosus NJ551 and bacillus coagulans BC01, wherein the lactobacillus rhamnosus NJ551 strain is preserved in China Center for Type Culture Collection, and the preservation number is CCTCC NO: M2016157; and the bacillus coagulans BC01 strain is preserved in China center fortype culture Collection, and the preservation number is CCTCC NO: M2017813. The probiotic composition provided by the invention can realize or exceed the effects of restoring or improving the intestinal mucosa permeability, NK cell killing rate and serum gamma-interferon (IFN-gamma) and TNF-alpha content of mice, which can be realized by single bacteria at a relatively large intake amount. The probiotic composition provided by the invention is beneficial to improvement of immunity.

The invention discloses an anti-depression method for fixed-point release of short-chain fatty acids by virtue of acylated starch, and belongs to the anti-depression field of the acylated starch. Theacylated starch is taken as a carrier of the short-chain fatty acids and is used for simulating a physiological state to realize the fixed-point release of the short-chain fatty acids in large intestines, depression-relevant physical indexes such as depression phenotypes, ACTH, CS and 5-HT of mice are detected through animal experiments, and the acylated starch capable of realizing an anti-depression function is screened and determined through the fixed-point release of the short-chain fatty acids in intestinal tracts of the mice. The acylated starch provided by the invention is capable of relieving despondent behaviors of the despondent mice, increasing the synthesis level of neurotransmitters and relieving hypothalamus-pituitary-adrenal axis hyperfunctions caused due to the pressure. Byutilizing the anti-depression method, the fixed-point release of the short-chain fatty acids in the intestinal tracts can be realized, and the method can be taken as a diet method which targets to environments in the intestinal tracts, is relatively low in cost and is capable of relatively safely and effectively intervening depressive disorders.

The invention discloses selenium-enriched probiotics for affecting mouse diarrhea and intestinal canal florae caused by irinotecan. Mouse models suffering from diarrhea caused by the irinotecan are established, the selenium-enriched probiotics are administered through long-term intragastric administration, and influence on the mouse diarrhea and intestinal canal florae caused by the irinotecan caused by the selenium-enriched probiotics is evaluated. Mice of an experimental group are administered with the selenium-enriched probiotics every day through intragastric administration, and body weight, diarrhea levels, mouse immunity indexes, intestinal canal florae and ileum tissue structures of the mice are measured. A result shows that the selenium-enriched probiotics can inhibit loss of weight and lowering of immunologic functions caused by the irinotecan; the diarrhea incidence rate and average diarrhea level of the mice are lowered, and the mouse diarrhea caused by the irinotecan is relieved; the content of clostridium, escherichia coli and bacteroides related to beta-D-glucuronidase is lowered, and the content of bifidobacterium in an intestinal canal is increased; and the injury to intestinal canal mucosae, cells and glands of the mice induced by the irinotecan is relieved.

The invention relates to technical field of functional food and medical health care, and discloses application of a broadleaf holly leaf aqueous extract and a drug composition for regulating intestinal microecology. The invention provides application of the broadleaf holly leaf aqueous extract to preparation of a drug for regulating the intestinal microecology, and the drug composition for regulating the intestinal microecology. Through animal experiments, the application of the broadleaf holly leaf aqueous extract to regulating of the intestinal microecology is studied, it is found that by improving diversity of mice intestinal flora, the broadleaf holly leaf aqueous extract effectively regulates intestinal flora disturbance and improves the barrier function of the intestinal tract, lowers expression of inflammatory factors of intestinal tissue, promotes secretion of intestinal mucins, and thus achieves the effects of lowering lipid and losing weight, lowering blood glucose and lowering fat accumulation; and it shows that the broadleaf holly leaf aqueous extract can regulate diseases of obesity, type 2 diabetes, non-alcoholic fatty liver disease and the like caused by intestinal flora disturbance.

The invention discloses a medicine for relieving alcoholic intestinal injury, and belongs to the technical field of microorganisms and medicines. The invention provides a medicine capable of preventing and / or treating alcoholic intestinal injury or alcoholic liver injury. The effective component of the medicine is Lactobacillus rhamnosus CCFM1119, and the Lactobacillus rhamnosus CCFM1119 can effectively relieve alcoholic intestinal injury and alcoholic liver injury, and is specifically embodied in (1) significantly improving the mRNA expression level of intestinal tight junction protein of analcohol-molded mouse; (2) significantly reducing the content of endotoxin (LPS) in serum of the alcohol-molded mouse; (3) significantly reducing the activity of alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) in serum of the alcohol-molded mouse; and (4) significantly improving pathological injury of liver tissue of the alcohol-molded mouse.

The invention discloses a method for evaluating biosafety by using mouse intestinal flora. According to the method, mouse intestinal flora is used as a biological model, mixed bacteriophage separatedfrom deep sea sediments is added into the biological model, and continuous treatment is performed for 3 days. After one week, an excrement sample of the mouse is taken to perform 16S rRNA gene sequencing, physiological indexes of the mouse are measured and compared with a control sample to determine the influence of the deep-sea bacteriophage on the intestinal flora structure of the mouse and thehealth of the mouse. Compared with a control group, if significant bacterial abundance changes and mouse physiological index changes exist in the three repetitions in the treatment group, it is provedthat the group of deep sea bacteriophage has the biosafety problem. The invention provides a method for evaluating the biological safety of the deep sea bacteriophage.

The invention discloses an efficient and high-activity mouse intestinal epithelium and immune cell separation and extraction method, and belongs to the technical field of biological cell extraction. The intestinal epithelial cells, the interepithelial immune cells and the intestinal intrinsic layer immune cells separated and extracted by the method are high in yield and high in activity, and can be widely applied to related researches of intestinal mechanical barriers and immune barriers. Compared with the existing method, the separation and extraction steps are simple, the consumed time is greatly reduced, the single cell separation and purification can be completed within about 3.5 hours generally, and the subsequent research can be more efficiently carried out.

The invention relates to new use of pravastatin and particularly relates to use of the pravastatin in preparation of drugs for preventing or / and treating intestinal ischemia reperfusion injury. Compared with the prior art, the invention has the following beneficial effects that the pravastatin is used for preventing or / and treating the intestinal ischemia reperfusion injury, actions of the drug are verified on a constructed classical intestinal ischemia reperfusion model, and a verification result displays that the pravastatin obviously improves intestinal ischemia reperfusion induced intestine tissue damage of a mouse, increases the survival rate of the mouse, inhibits expression of inflammatory factors, is remarkable in effect and low in side effect and is safe and non-toxic.

The invention provides an application of a blood-derived enzymatic hydrolysis peptide in the preparation of a drug for inhibiting intestinal inflammation in animals. Specifically, pig blood is used as a raw material and purified through grinding, enzymolysis, suction filtration, centrifugation, ultrafiltration and other processes to obtain A biologically active peptide that has the effect of inhibiting intestinal inflammation in animals. The dried active peptide is in the form of thin layer, powder, powder with lighter color. The biologically active peptide has the effect of inhibiting intestinal inflammation judged by its inhibitory effect on mouse intestinal inflammation, and can be used as feed, feed additive, pharmaceutical auxiliary material, etc. The blood-derived enzymatic peptide for inhibiting intestinal inflammation of the present invention is non-toxic and has no side effects, does not remain in animals, and has significant economic and social contributions. The invention will promote the rapid development of active peptide biological products in the pharmaceutical industry and the feed industry.

The invention discloses a bifidobacterium animalis subsp. Lactis strain WKB148 as well as a product and application thereof, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis subsp. Lactis strain WKB148 is CCTCC (China Center for Type Culture Collection) NO: M 2022189. The invention also provides a product for regulating pathogenic bacteria or beneficial bacteria and a product for regulating the content of short-chain fatty acids based on the strain WKB148. The bifidobacterium animalis subsp. Lactis strain WKB148 can be used for increasing the relative abundance of a second-generation probiotic Akkermansia spp. In the intestinal tract of a mouse, effectively inhibiting pathogenic bacteria such as shigella flexneri and the like, and increasing the relative abundance of a protective bacterium Allobaculum spp. In the intestinal tract of the mouse. The content of short-chain fatty acid in mouse excrement can be increased, and the method has a very wide application prospect in the aspect of regulating the intestinal flora structure.

The invention discloses a strain of Lactobacillus paracasei capable of relieving alcoholic intestinal damage and an application thereof, belonging to the technical field of microorganisms and the technical field of medicine. The invention provides a medicine that can prevent and / or treat alcohol-induced intestinal damage or alcohol-induced liver damage. The active ingredient of the medicine is Lactobacillus paracasei CCFM1120, and the Lactobacillus paracasei CCFM1120 can effectively relieve Alcohol-induced intestinal injury and alcohol-induced liver injury are embodied in: significantly increasing the mRNA expression of tight junction protein in the intestinal tract of alcoholic model mice; significantly reducing the content of endotoxin in the serum of alcoholic model mice; The activities of alanine aminotransferase and aspartate aminotransferase in the serum of model mice; significantly reduce the level of oxidative stress in the liver of alcohol model mice; significantly improve the pathological damage of alcohol model mice liver tissue.

The disclosure discloses the application of a 1-benzhydryl-4-methylpiperazine compound in the preparation of antidepressant drugs, which belongs to the field of medicine. The compound 1-benzhydryl-4-((1-benzene 1H-1,2,3-triazol-4-yl)methyl)piperazine can significantly improve the depression-like behavior in chronic unpredictable stress model mice. Mechanistic studies have shown that the compound 1‑benzhydryl‑4‑((1‑phenyl‑1H‑1,2,3‑triazol‑4‑yl)methyl)piperazine can improve the effects of chronic unpredictable stress Induced intestinal flora disturbance in mice; and has a protective effect on the integrity of the intestinal barrier and blood-brain barrier.